Patent dispute over erythropoietin terminated

Published: 2003-07-30 06:58:00

Updated: 2003-07-30 06:58:00

Darae patent office said that the domestic production of erythropoietin, an biotechnology based antianemic drug, may be further activated, as CJ, a local pharmaceutical firm, won the patent dispute touched off by the U.S.-based Genetics Institute (GI) in a trial to confirm the scope of patent rig...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK